| Filed On | Filing |
|---|---|
| 16 Nov 2026 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): |
| 13 Nov 2026 |
8-K: Regulation FD Disclosure; Other Events
Primary efficacy endpoint achieved based on preliminary results from a November 5th data evaluation |
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
REDWOOD CITY, Calif., November 5, 2026 – Rezolute, Inc. (Nasdaq: RZLT) (Rezolute or the Company), a late-stage ultra-rare, metabolic disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI), ... |
| 29 Oct 2026 |
8-K: Regulation FD Disclosure
A Late - stage Ultra - rare Disease Company Treating Refractory Hypoglycemia Corporate Presentation |
| 14 Oct 2026 |
8-K: Regulation FD Disclosure
REDWOOD CITY, Calif., October 14, 2026 – Rezolute, Inc. (Nasdaq: RZLT) (Rezolute or Company), a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI), today announced... |
| 05 Oct 2026 |
8-K: Regulation FD Disclosure
The Agency reiterated its commitment to addressing the unmet need for treatment |
| 24 Sep 2026 |
8-K: Results of Operations and Financial Condition
REDWOOD CITY, Calif., September 24, 2026 – Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare rare disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI), ... |
| 02 Jun 2026 |
8-K: Regulation FD Disclosure
6 of 8 participants have already met the responder criterion for the study’s primary endpoint |
| 12 May 2026 |
8-K: Results of Operations and Financial Condition
REDWOOD CITY, Calif., May 12, 2026 – Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today reported financial re... |
| 04 May 2026 |
8-K: Regulation FD Disclosure
Rezolute Announces Oral Presentation of Results From its Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism at the Pediatric Endocrine Society Annual Meeting |
| 24 Mar 2026 |
8-K: Regulation FD Disclosure
FDA encourages the Company to submit comprehensive data from sunRIZE and the ongoing open-label extension to inform next steps for the program |
| 12 Feb 2026 |
8-K: Results of Operations and Financial Condition
REDWOOD CITY, Calif., February 12, 2026 – Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today reported financi... |
| 07 Jan 2026 |
8-K: Regulation FD Disclosure
A Late - stage Rare Disease Company Treating Hyperinsulinism Corporate Presentation |
| 21 Nov 2025 |
8-K: Submission of Matters to a Vote of Security Holders
Rezolute, Inc. (the “Company”) held its 2026 annual meeting of stockholders on November 19, 2025. The meeting was held virtually at www.virtualshareholdermeeting.com/RZLT2025. As of the record date, September 22, 2025, there were a total... |
| 12 Nov 2025 |
8-K: Regulation FD Disclosure
Rezolute Investor Event: Ersodetug Development Program November 10, 2025 |
| 06 Nov 2025 |
8-K: Results of Operations and Financial Condition
REDWOOD CITY, Calif., November 6, 2025 – Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today reported financial results and prov... |
| 21 Oct 2025 | 8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +1 more |
| 17 Sep 2025 |
8-K: Results of Operations and Financial Condition
REDWOOD CITY, Calif., September 17, 2025 – Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today reported financial results and pr... |
| 02 Sep 2025 |
8-K: Regulation FD Disclosure
A Late - stage Rare Disease Company Treating Hyperinsulinism Corporate Presentation NASDAQ: RZLT |
| 20 Aug 2025 |
8-K: Entry into a Material Definitive Agreement; Departure/Election of Directors or Officers; Compensation +1 more
Experienced commercial and biopharmaceuticals leader to spearhead launch strategy and global market readiness for ersodetug |
Loading...